Eloralintide for Adults With Obesity Who Still Carry Excess Weight on a Weekly Incretin
Tests eloralintide against placebo in adults with obesity already taking a weekly incretin.
Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Key facts
- Where
- Afula, Atlit, Beersheba, Hadera, Haifa, Holon, Jerusalem, Kfar Saba, Kiryat Motzkin, Netanya, Petah Tikva, Ramat Gan, Rehovot, Sakhnin, and Tel Aviv, IsraelSee the 17 sites
- Phase
- Phase 3
Where in Israel
- Emek Medical CenterAfula, IsraelNot yet recruiting
- Clalit Health Services - AtlitAtlit, IsraelNot yet recruiting
- Soroka Medical CenterBeersheba, IsraelNot yet recruiting
- Hillel Yaffe Medical CenterHadera, IsraelNot yet recruiting
- Rambam Health Care CampusHaifa, IsraelNot yet recruiting
- Edith Wolfson Medical CenterHolon, IsraelNot yet recruiting
- Hadassah medical CenterJerusalem, IsraelNot yet recruiting
- Meir Medical CenterKfar Saba, IsraelNot yet recruiting
- Maccabi health care services - Qiryat MotzkinKiryat Motzkin, IsraelNot yet recruiting
- Laniado HospitalNetanya, IsraelNot yet recruiting
- Rabin Medical CenterPetah Tikva, IsraelNot yet recruiting
- Rabin Medical Center - Hasharon CampusPetah Tikva, IsraelNot yet recruiting
- Sheba medical centerRamat Gan, IsraelNot yet recruiting
- Kaplan Medical CenterRehovot, IsraelNot yet recruiting
- Clalit Health Services - Sakhnin Community ClinicSakhnin, IsraelNot yet recruiting
- Diabetes Medical CenterTel Aviv, IsraelNot yet recruiting
- Sourasky Medical CenterTel Aviv, IsraelNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07392190EU 2025-523659-73-00
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.Read full original descriptionShow less
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.
Participation in the study will last about 80 weeks.
Inclusion: Are on stable incretin therapy at screening; With persistent obesity or overweight defined as:; ≥30 kg/m2 OR; ≥27 kg/m2 with at least one existing obesity related complication at screening:; hypertension; dyslipidemia; obstructive sleep apnea; cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or; type 2 diabetes; Have a stable body weight (<5% body weight change) at screening.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have taken any of the following antihyperglycemic medications within 90 days before screening:; dipeptidyl peptidase-4 (DPP-4) inhibitors; amylin analogs; insulin; Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.